(Q39874482)

English

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

scientific article published on 10 March 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes (English)

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

1 reference

based on heuristic

inferred from title

cell differentiation

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

0 references

author name string

C Alfaro

1

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

N Suarez

2

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

A Gonzalez

3

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

S Solano

4

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

L Erro

5

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

J Dubrot

6

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

A Palazon

7

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

S Hervas-Stubbs

8

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

A Gurpide

9

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

J M Lopez-Picazo

10

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

E Grande-Pulido

11

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

I Melero

12

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

J L Perez-Gracia

13

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

language of work or name

0 references

publication date

10 March 2009

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

100

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

7

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

1111-1119

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604965

0 references

Immunotherapy for renal cell cancer in the era of targeted therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Metastatic renal cell carcinoma: recent advances and current therapeutic options

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Renal cell carcinoma tumors induce T cell apoptosis through receptor-dependent and receptor-independent pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

A quantitative analysis of kinase inhibitor selectivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Immunostimulatory monoclonal antibodies for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Clinical translation of angiogenesis inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

22 September 2017

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

20 August 2018

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

20 August 2018

Filter Buffy Coats (FBC): a source of peripheral blood leukocytes recovered from leukocyte depletion filters.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

20 August 2018

Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

20 August 2018

Gene therapy of cancer with interleukin-12.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

20 August 2018

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

20 August 2018

Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

20 August 2018

Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670006

20 August 2018

Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A

1 reference

https://pubmed.ncbi.nlm.nih.gov/19277038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19277038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/19277038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dendritic cells in cancer immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19277038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function

1 reference

https://pubmed.ncbi.nlm.nih.gov/19277038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dendritic cells in vivo: a key target for a new vaccine science

1 reference

https://pubmed.ncbi.nlm.nih.gov/19277038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/19277038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6604965

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39874482&oldid=2091884317"